Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis.

Biomolecules · 2024 · PMC11506457 · PMID 39456169

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

NTZ at 30 μM, a dose approximately double the predicted IC50 for TTJ-TSC2-null cell growth inhibition, showed a trend for inhibition of about 50% of mTORC1-driven pS6 (Ser235/236) and, similar to Rapamycin, did not inhibit p4E-BP1 (Thr37/46).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.